Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and m...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Alberto Esteban-Fernández, Alejandro Recio-Mayoral, Raquel López-Vilella, Gregorio de Lara, Moisés Barrantes-Castillo, Inés Gómez-Otero, Julio Nuñez-Villota, Carolina Robles-Gamboa, José López-Aguilera, Ángel Iniesta-Manjavacas, Paula Fluviá, Francisco Pastor-Pérez, Laia Belarte-Tornero, Gonzalo Alonso-Salinas, Pablo Díez-Villanueva
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-01-01
Schriftenreihe:	Frontiers in Cardiovascular Medicine
Schlagworte:	vericiguat worsening heart failure guideline-directed medical therapy VERISEC registry heart failure reduced ejection fraction
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!